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Abstract  
A lack of evidence to guide the design of age-appropriate and acceptable dosage forms has been a 
longstanding knowledge gap in paediatric formulation development. The Children’s Acceptability of 
Oral Formulations (CALF) study captured end-user perceptions and practices with a focus on solid 
oral dosage forms, namely tablets, capsules, chewables, orodispersibles, multiparticulates 
(administered with food) and mini-tablets (administered directly into the mouth). A rigorous 
development and testing phase produced age-adapted questionnaires as measurement tools with 
strong evidence of validity and reliability. Overall, 590 school children and adolescents, and 428 adult 
caregivers were surveyed across hospitals and various community settings. Attitudes towards dosage 
forms primarily differed based on age and prior use. Positive attitudes to tablets and capsules 
increased with age until around 14 years. Preference was seen for chewable and orodispersible 
preparations across ages, while multiparticulates were seemingly less favourable. Overall, 59.6% of 
school children reported willingness to take 10mm diameter tablets, although only 32.1% of 
caregivers perceived this size to be suitable. While not to be taken as prescriptive guidance, the results 
of this study provide some evidence towards rational dosage form design, as well as methodological 
approaches to help design tools for further evaluation of acceptability within paediatric studies. 
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1. Introduction 
The maturing field of clinical pharmaceutics has steered a drive towards patient-ceneterd formulation 
development (Liu et al., 2014, Florence, 2010, Stegemann et al., 2016). This is particularly evident in 
the area of paediatrics, where evolving regulatory reforms have strengthened a global focus to 
facilitate authorisation and access to safe and high quality medicines for children. These drivers have 5 
transformed this once niche area into an integral part of the drug development process, with both the 
European Medicines Agency (EMA) and Food and Drug Administration (FDA) obligating 
investigators to outline comprehensive formulation development strategies through Paediatric 
Investigation Plans (PIPs) and Pediatric Study Plans (PSPs), respectively. The rationale for choice, 
including advantages and disadvantages of dosage form design needs to be discussed and justified, 10 
with a demonstrably positive benefit-risk balance (EMA, 2013). 
 
In its pivotal pharmaceutical development guideline, the EMA defines an age-appropriate paediatric 
medicine as one “whose pharmaceutical design makes it suitable for use in the target age group(s)”, 
with pharmaceutical design encompassing factors such as composition, dosage form, dosing 15 
frequency, and packaging (EMA, 2013). A strong emphasis is placed on ensuring that formulations 
are acceptable to patients, by demonstrating “the overall ability and willingness of the patient to use 
and its caregiver to administer the medicine as intended” (EMA, 2013, Kozarewicz, 2014). Indeed, 
designing formulations that are both suitable and favourable for end-users can benefit patient 
adherence and ultimately therapeutic outcomes; thus, it is just to insist that this is evaluated during 20 
pharmaceutical and clinical development. However, there is often limited information available about 
the taste characteristics of the active pharmaceutical ingredient (API) when a PIP is submitted, to give 
indications about taste masking techniques required for a paediatric dosage form. This is coupled with 
a well-acknowledged paucity of evidence-based data to help define key formulation characteristics 
that are shown to be age-appropriate or acceptable across this highly heterogeneous population 25 
(Ranmal and Tuleu, 2013, van Riet-Nales et al., 2011, EMA, 2006). Therefore, it can be particularly 
challenging for formulation scientists to propose suitable approaches for clinical investigations, 
including preliminary or enabling preparations, as well as for final commercial products. In 2009, 
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nearly half of all PIP applications were referred to a specialised Formulation Working Group of the 
Paediatric Committee (PDCO FWG). Overall 92% of the 125 pharmaceutical formulations proposed 30 
had at least 1 issue; 96 were related to the pharmaceutical form, including 21 regarding appropriate 
choice of dosage form, while patient acceptability of 12 oral dosage forms was either not addressed or 
considered inadequate (Quijano Ruiz et al., 2014).  
 
With the aim of addressing this important knowledge gap, the Children’s Acceptability of Oral 35 
Formulations (CALF) study involved eliciting the unique views of school children, adolescents, and 
their caregivers, with a specific focus on solid oral dosage forms (SODFs). Suitability of dosage form 
design is one of the foremost challenges in paediatric drug delivery research, and this aspect can 
influence other important factors such as the need and choice of excipients or the necessity of devices. 
There has been a notable shift towards the development of solid formulations over liquids, given the 40 
limitations with stability, palatability, and costs associated with the latter (Lajoinie et al., 2014, 
Venables, 2013, Walsh et al., 2014). Rapidly advancing innovative technologies such as (oro-
)dispersible, multiparticulate and chewable preparations offer the key advantages of solid dosage 
forms, together with the flexibility of dosing and ease of ingestion traditionally associated with 
liquids. Development of appropriate formulations is a global health challenge and the distinct 45 
requirements in resource-limited settings also requires due consideration (Craig et al., 2009, Sosnik et 
al., 2012). The World Health Organization (WHO) has spearheaded various initiatives in the area of 
paediatric medicines, including the aptly named “Make Medicines Child Size” campaign. In their key 
points to consider document, the WHO advocates the development of flexible SODFs, defined as 
those that can be administered in more than one manner, for example, tablets that can be dispersed in 50 
water or breast milk, or alternatively, be swallowed intact (WHO, 2012). Nevertheless, prior to 
adopting these changes in policy, there is a critical need to understand end-user attitudes and 
preferences to ensure that these proposals are truly patient-centric.  
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2. Material and methods 
2.1. Development and testing of research instruments 55 
A quantitative data collection approach was used in the CALF study, primarily using age-adapted 
questionnaires for children aged 6 to 9 years (CQ: children’s questionnaire) and 10 years and over 
(YPQ: young people’s questionnaire), and a separate questionnaire for caregivers (AQ: adult 
questionnaire). Based on the principles of patient and public involvement (PPI) in research, the 
development, pre-testing and piloting of all research materials was completed through an iterative, 60 
systematic process involving 140 contributors. This mixed-method approach included study 
conceptualisation with a multi-disciplinary focus group, cognitive and observational interviews, and 
quantitative assessments of validity and reliability (Table 1). 
 
Figure 1 illustrates the six SODFs of interest and the scale used to assess end-user attitudes. The 3-65 
item, 5-point scale evaluated distinct but inter-related components: affective - whether the dosage 
form was liked or disliked; behavioural - willingness to take the dosage form; and cognitive - whether 
the dosage form was perceived as easy or difficult to take. This theoretical tripartite model derived 
from attitude psychology research has been utilised across various disciplines to capture an overall 
‘global evaluation’ of an object based on the synergism of these components. The multicomponent 70 
scale demonstrated high internal consistency, as assessed by Cronbach’s alpha (α = 0.782 - 0.903). 
Importantly, this approach enabled the acceptability of each dosage form to be captured, a construct 
that is distinct from preference. Moreover, the scale accurately reflected the EMA’s definition of 
acceptability as a measure of both ability and willingness (EMA, 2013). Children themselves 
preferred the multicomponent scale over single-item measures, and it was found to be appropriate 75 
with respect to comprehension, respondent burden, and sensitivity in capturing attitudinal differences.  
 
In addition to attitudes and acceptability, the questionnaires addressed preferences for dosage forms 
and their attributes, as well as current experiences and practices with medicines. Demographic 
variables captured included age, gender, ethnicity and socioeconomic status (SES). To enable young 80 
people to self-report SES, the validated Family Affluence Scale (FASII) developed for the 
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international WHO Health Behaviour in School-Aged Children (HBSC) study was used with the 
permission of the research team (Currie et al., 2008a, Currie et al., 2008b). Presence of a chronic 
health condition (CHC) was captured using a dichotomous question and defined as “symptoms, 
diseases or conditions that affect [respondents] for 3 months or longer”. For younger respondents 85 
completing the CQ, ethnicity and SES were proxy-reported by caregivers. Overall, test-retest 
reliability of the instruments was found to be acceptable as assessed by Cohen’s kappa, ranging from 
Κ = 0.43 - 0.77 for individual questionnaire items. 
 
2.2. Study design 90 
In the main study, large-scale data collection was completed via opportunistic, purposive sampling 
across various hospitals, pharmacies, schools, and community settings in the UK, and a smaller sub-
study in Montreal, Canada. Questionnaires were self-completed independently by children and their 
caregivers under the supervision of the researchers. Items were read out verbatim to younger 
participants where necessary. As a requirement of ethical approval, questionnaires used in Canada 95 
were translated into French to cater to Quebec’s francophone population. Forward translation was 
initially completed by the researcher completing fieldwork in the setting, and translated drafts were 
reviewed independently by two bilingual French speakers. 
 
Following completion of the questionnaires, participants’ perceived acceptability of tablet and capsule 100 
sizes was assessed using physical models of varying dimensions. Specifically, these were round, 
white, flat-faced tablets of 5mm, 8mm, 10mm and 13mm diameter, and white, capsules in sizes #3, 
#1, #0 and #00. Children and young people selected the largest size they would be willing to swallow 
intact, while caregivers reported the sizes that they would deem most suitable for their child. 
Participants were not required to swallow the sizes that they had selected.  105 
 
2.3. Ethical approval 
In the UK, research conducted in community settings was approved by the local university research 
ethics committee (REC), while data collection in hospitals was approved by the National Research 
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Ethics Service (NRES) REC (ref: 12/YH/0121). In Canada, approval was granted by the Central 110 
Committee of Ethics Research (CCER) of the Ministry of Health and Social Services (MSSS) in 
Quebec. All participants were provided with information sheets, and written assent and consent was 
obtained from both children and adults respectively, where needed as a requirement of ethical 
approval. Based on guidance from NRES, five sets of age-adapted information and consent forms 
were designed, appropriate to various age ranges and styles, including pictorial content for the 115 
youngest participants (NRES, 2011).  
 
2.4. Data management and analysis 
During fieldwork, researchers administered laminated copies of questionnaires to respondents, which 
were then photocopied or transcribed to identical pages. Data was uploaded to Qualtrics (Provo, Utah) 120 
for cleaning and two-step verification. Descriptive and statistical analysis completed using Microsoft 
Excel (version 14.4.1, Microsoft Corporation) and SPSS (version 22, SPSS Inc., Chicago). Mean 
scores from scaled items were compared using t-tests and ANOVA, with non-parametric Kruskal-
Wallis H tests and Mann-Whitney U tests used for sensitivity analysis. A univariate general linear 
model (GLM) analysis was completed to determine whether there was an interaction effect between 125 
demographic variables and mean attitudinal scores. Chi-square tests for association (χ2) were used for 
statistical comparisons of categorical data. Since data analysis involved multiple hypothesis testing, 
the Bonferroni method was used to correct for multiple comparisons. A p-value significance threshold 
of 0.05 was used throughout. 
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3. Results and discussion 130 
3.1. Participant demographics  
In the main CALF study, 590 school children and adolescents were surveyed, 48% in hospital 
settings, 36% in pharmacies or other community settings, and 16% in schools. School children are 
defined as those aged 6 to 11 years and adolescents aged 12 to 17 years. Participants’ demographics 
and health backgrounds are summarised in Table 2. As intended, research across various clinical and 135 
non-clinical settings ensured that the sample of participants was diverse, including patients with a 
CHC or acute illness, as well as healthy or medicines naïve children. A further 428 questionnaires 
were completed by adult caregivers, 284 as caregivers of school children and 144 of adolescents. The 
majority of these were female (78.5%) and parents (94.2%). In Canada, over three-quarters of the 
questionnaires were completed in English, 92 by children and adolescents, and 83 by caregivers.  140 
 
3.2. Attitudes and preferences 
The CALF study has been unique in directly comparing attitudes and preferences towards six 
different SODFs. To capture overall attitudes, ratings for each item on the tripartite scale (Figure 1) 
were scored from 1 to 5, and summated to produce an attitudinal score between 3 and 15. Figure 2 145 
illustrates the rank order of acceptability based on mean summated attitudinal scores. Additionally, 
the results from the behavioural component of the scale are illustrated, reported as the willingness to 
take the dosage form for children and adolescents, and willingness to purchase the dosage form as an 
over the counter (OTC) paediatric medicine among caregivers. Mean attitudinal scores from school 
children and adolescents were compared for different demographic and healthcare variables (Table 3). 150 
This analysis demonstrates that attitudes were most significantly affected by age and prior use of 
dosage forms. Univariate general linear model analyses showed no interaction effect between 
attitudinal scores and the three independent demographic variables, age, sex and SES (completed for 
UK respondents for whom SES data was reported).  
 155 
3.2.1 Tablets and capsules 
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As shown in Table 3, mean attitude scores for tablets and capsules increased with age (p<0.001) 
indicating more favourable perceptions, whereas scores for more novel dosage forms tended to 
decrease. Tukey’s post-hoc analysis highlighted a significant difference in attitudes to these dosage 
forms until the age of 12 to 13 years; from the age of 14 years, attitudes towards both remained stable. 160 
Interestingly, the same trend was observed among caregivers, with no significant difference in mean 
scores from the age of 14 years. Related to this, prior use of these dosage forms increased in early 
adolescence; only 38.8% of 10 to 11 years olds reported prior use of tablets versus 63.6% of 12 to 13 
year olds. This difference was less pronounced for capsules (20.1% and 36.5% respectively). Similar 
rates of prior use have been reported elsewhere, including a US survey which found that nearly all 165 
respondents aged 12 years and over had used SODFs in the past (Polaha et al., 2008).  
 
In the present study, mean attitudinal scores among caregivers tended to be lower and more variable 
than paediatric scores for all SODFs. T-tests confirmed statistically significant differences in mean 
scores among school children and their caregivers for tablets (p<0.001) and capsules (p<0.001), 170 
illustrated by the wider difference in means in Figure 2. Parents and caregivers play an important role 
in paediatric medicines use, from purchasing OTC medicines to taking primary responsibility for 
medicines administration. Nevertheless, caregiver perspectives of acceptability should be considered 
in a complementary manner, rather than as data that takes precedence or substitutes children’s own 
views. Additionally, adults have previously shown inaccurate preconceptions that can affect their 175 
ability to predict children’s behaviour and choices, including autonomy of medicines use (Hämeen-
Anttila and Bush, 2008) and ability to swallow small placebo tablets (Meltzer et al., 2006).  
 
Children’s age has conventionally been seen as the primary factor when considering dosage form 
suitability, with 6 years historically cited as the age from which tablets and capsules may be 180 
considered suitable (EMA, 2006). Nevertheless, evidence has shown that children as young as 3 years 
old are able to swallow conventional tablets and capsules (Nahirya-Ntege et al., 2012, Kaplan et al., 
2010, Czyzewski et al., 2000).  On the other hand, older children and adolescents have reported 
swallowing difficulties, including as a barrier to adherence in chronic conditions (Hansen et al., 2008, 
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Polaha et al., 2008, Hommel and Baldassano, 2010, Modi et al., 2013). The present study highlights 185 
that while age is a critical factor, other aspects such as health background are also important 
characteristics to consider. While prior use of dosage forms was effective at capturing differences in 
attitudes, presence of a CHC showed less sensitivity. Overall, tablets and capsules were ranked the 
least favoured dosage forms for school children (Figure 2); nevertheless, school children reporting 
frequent prior use had mean scores comparable to those of adolescents. Feedback from some of the 190 
youngest participants revealed positive perceptions, including for example, that “tablets are adult 
medicines [which are] stronger and will make me better quicker” (female participant aged 6 years 
old). 
 
In addition to determining attitudes, participants’ preferences were captured through direct 195 
comparison of dosage forms (Figure 3). Both school children and adolescents showed a stronger 
preference for tablets over capsules, and indeed, tablets were ranked the most acceptable of all six 
SODFs among adolescents and their caregivers. The reasoning behind positive attitudes to tablets 
included familiarity, as well as ease and rapidity of ingestion. Barriers to the acceptability of capsules 
included their large size, and in some instances, the misconception that they are made from plastic. A 200 
small proportion of school children (12.7%) preferred neither dosage form, though nearly half 
reported a neutral or negative response to the behavioural component of the scale. It is important to 
note that barriers to acceptability are not limited solely to the paediatric population. Incidences of 
medication related swallowing difficulties might have contributed to these findings, as this a well-
known problem across all ages. A small number of studies investigating this issue in the general adult 205 
population have reported prevalence rates between 9% to 40% (Marquis et al., 2013, DeRoche et al., 
2003, Schiele et al., 2013). Remarkably, these studies have indicated a gender effect, with a 
significantly higher frequency of difficulties among females compared to males. In the CALF study, 
male respondents tended to have more positive mean scores for all dosage forms; however, the 
superior scores for tablets and capsules in adolescents were the only differences to reach statistical 210 
significance. 
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Collectively, this evidence suggests that a useful approach to help guide pharmaceutical development 
is to assess the attributes of currently available commercial products, and determine whether these are 
acceptable and capable of being administered as authorised in practice. Specifically, such research 215 
should focus on capturing patients’ actual experiences and practices. Moreover, this assessment 
should be completed for different age groups, and across diseases and indications, to help determine 
the extent to which unique, novel paediatric dosage forms are required. Indeed, in many cases, dosage 
forms developed for the paediatric population may be suitable for older adults, as well as the 
seemingly large number of adult patients who struggle to swallowing medicines. In certain chronic 220 
conditions, patients may have acquired the ability to swallow monolithic dosage forms intact. In such 
cases, tablets of appropriate dose strengths or with functional score lines may present a suitable and 
beneficial option for paediatric patients. Flexibility with capsules may be achieved if they are labelled 
for administration intact or via sprinkling of the contents. Indeed, tablets and capsules offer important 
advantages including accuracy of dosing, taste-masking, and ease and cost-effectiveness of 225 
manufacture. These benefits should be acknowledged in cases where these dosage forms are a 
potential option for paediatric medicinal products. 
 
3.2.2 Novel dosage forms 
Multiparticulates and mini-tablets show considerable promise in the paediatric population, as they 230 
offer the coveted goal of ease of administration and dose flexibility, and potentially have wide 
applicability through adjustment of dose quantity or volume. Recent studies assessing the 
acceptability and swallowability of placebo mini-tablets have been a notable emergence in the field, 
particularly as a dosage form for neonates and infants (Klingmann et al., 2013, Klingmann et al., 
2015, Thomson et al., 2009, van Riet-Nales et al., 2013, Kluk et al., 2015).  An important objective of 235 
the CALF study was to determine acceptability and perceptions of these dosage forms in older 
children, since very little is reported in the literature. A critical factor to note is the respective 
descriptions used to effectively discriminate both dosage forms; mini-tablets were presented as 
multiple discrete units administered directly into the mouth, while multiparticulates were described as 
being administered with soft food. While both dosage forms can potentially be administered either 240 
12 
 
way, this differentiation was included for clarity and brevity. Future research evaluating these dosage 
forms should assess the impact of these modes of administration on end-user acceptability.  
 
In the CALF study, mini-tablets were relatively well accepted across ages, whereas multiparticulates 
became markedly less favourable with increasing age. Post-hoc analysis showed the decrease in mean 245 
attitude score for multiparticulates at the age of 10 to 11 years (Table 2) was most significant 
(p=0.004). Anecdotal feedback identified various factors as potential barriers to acceptability, 
including perceptions that they were infantile (particularly among older children), reservations about 
administering medicines with food (particularly in terms of consequent adverse effects to taste), and 
concerns about knowing whether the whole dose had been administered. This is an important 250 
consideration during the development and eventual labelling of multiparticulate products. 
Administration of powders and granules with soft, semi-solid foods has been deemed to be suitable 
for infants from the age of 6 months (EMA, 2013); however, to ensure the widest applicability, both 
direct administration in the mouth and mixing with food should be investigated. Adequate assurance 
of taste-masking and palatability should be ensured, as participants’ concerns are not unfounded. In 255 
the case of micronutrient sprinkle products for example, acceptability rates of over 90% have been 
reported by caregivers of infants (Zlotkin et al., 2003, Adu-Afarwuah et al., 2008). However, in one 
study, nearly of all caregivers reported that sprinkles had an unpleasant smell or taste, and that they 
changed the colour of food, both of which may negatively impact acceptability (Kounnavong et al., 
2011).  260 
 
In the present study, over 60% of school children and adolescents reported a willingness to take mini-
tablets; however, in direct comparison, nearly half of all adolescents preferred to take a single tablet 
over mini-tablets (Figure 3). As part of a recent clinical study, Musiime et al. reported that older 
children aged 4 to 13 years old who were able to swallow tablets found these more acceptable than 265 
mini-tablets that were administered with food (Musiime et al., 2014). Problems with taste and 
swallowing difficulties were reported by 50% and 13% of the cohort respectively for the mini-tablet 
product, while neither problem was reported with tablets. Concerns raised about mini-tablets in the 
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CALF study included handling difficulties, risk of aspiration or choking, and perceptions that they 
would become “stuck” in teeth or tonsils. An important evidence gap with both mini-tablets and 270 
multiparticulates is determining acceptability relative to dose quantity, and organoleptic properties 
including mouthfeel or grittiness. Future research assessing these dosage forms should also consider 
the modality for drug delivery and use of devices to facilitate administration. The CALF study 
captured some preferences with regards to administration, with 44.9% of young people, and 45.3% of 
caregivers favouring stickpacks or sachets. A further 22.8% and 14% respectively favoured capsules 275 
that could be opened, while the remaining respondents stated no preference.  
 
Age showed little effect on attitudes to orodispersible dosage forms, whereas with chewables, 
attitudinal scores decreased with age but remained highly favourable for both school children and 
adolescents. Chewables were also specifically preferred over orodispersibles and multiparticulates 280 
(Figure 3). From an anthropological perspective, this may be instinctive; the importance of chewing 
food is widely reiterated to children and mastication before swallowing is an innate mechanism for 
articles which enter the mouth (Mrsny, 2012). The natural tendency to chew was evidenced in the 
recent studies assessing acceptability and swallowing of mini-tablets, especially amongst those aged 2 
to 3 years old (Thomson et al., 2009, Klingmann et al., 2013). A large market research study found 285 
that parents in the US predominantly preferred chewables over other oral dosage forms in children 
aged 1 to 15 years, while German parents showed a stronger preference for effervescent tablets and 
lozenges. (Hermes Pharma, 2015). In contrast, Adams et al. found that caregivers in Tanzania 
preferred pills to be swallowed intact, over chewable forms for school aged children (Adams et al., 
2013). Notable differences in parental attitudes to orodispersible tablets have also been shown 290 
between European countries (Valovirta and Scadding, 2009). This disparity may be attributable to 
difference in familiarity and prior use of dosage forms, an important contributing factor identified 
from the CALF study. 
 
Based on this emerging evidence, chewables can be considered a preferred dosage form in cases 295 
where satisfactory organoleptic properties such as taste and mouthfeel can be achieved. Many 
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chewable medicines have been licensed and shown to be safe and well-tolerated in children from the 
age of 2 years (Michele et al., 2002). For younger participants, orodispersibles offer more potential 
with regards to ease of ingestion, while orodispersible mini-tablets or multiparticulates may add an 
important degree of dose flexibility or wider dose range where required. Multiparticulates and mini-300 
tablets should be considered to be evaluated to be administered with food or directly via suitable, age-
appropriate devices or packaging. Based on recent FDA guidance, multiparticulates labelled for 
administration via sprinkling should have a target size of 2.5mm (with no more than 10% variation 
over this to a maximum size of 2.8mm) to ensure adequate mouthfeel and reduce the risk of 
inadvertent chewing (FDA, 2012). In all cases, decisions regarding oral dosage form choice will often 305 
be principally governed by the taste profile and properties of the API and excipients.  
 
3.3. Dosage form attributes  
Attributes of dosage forms, such as size, shape and colour can be adapted to provide aesthetic final 
products that are acceptable to the end-user. Nevertheless, care must be taken to ensure that medicinal 310 
products do not appear too attractive or strongly resemble confectionary, and use of colouring agents 
is generally discouraged (EMA, 2013). Whatley et al. assessed the ability of healthy children aged 4 
to 11 years old to identify medicines; red and white bi-coloured capsules were more correctly 
identified as medicines compared to tablets, while 53% of children incorrectly identified pink tablets 
as “sweets” (Whatley et al., 2012). In the present study, dosage form size and taste were rated as very 315 
important by 56.8% and 55.3% of young people respectively. Interestingly, colour was ranked the 
least important attribute with 70.7% rating it is as not important. Almost half of all young people 
(48.8%) showed no specific preference for colour, whereas 25.6% preferred white medicines and 
25.6% preferred coloured medicines. Anecdotal feedback highlighted that young children themselves 
had concerns that medicines should not look too appealing, for example, one 12 year old male 320 
respondent stated“I’d prefer them [medicines] to be white [otherwise] I’d feel like I was taking 
something I wasn’t supposed to.”   From a regulatory perspective, other strategies are preferred for 
purposes of product differentiation, such as variability in size, shape, and embossing (EMA, 2013). 
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As part of the overall CALF study design, acceptability of tablet and capsule sizes was assessed using 325 
physical models, with participants selecting the largest size they perceived to be able to swallow, or 
that their child would be able to swallow. Notably, responses were based on perceived acceptability, 
as actual swallowability data was not captured within this or a follow-up study. Nevertheless, these 
findings present some indication of potential geometric characteristics to consider for further 
evaluation in larger studies. As illustrated in Figure 4, 59.6% of school children reported the 330 
willingness to take tablets of 10mm diameter or larger, while only 32.1% of caregivers found this size 
suitable. In comparison, 82.9% of adolescents and 77.1% of their caregivers found tablets of this 
diameter to be acceptable. Kokki et al. reported that 80% of children aged 1 to 9 years old were able 
to swallow 7mm tablets, while in their study, Meltzer et al. reported 84% of school-aged children 
could swallow tablets of the same size, with or without ordinary training (Kokki et al., 2000, Meltzer 335 
et al., 2006). For capsules, 15% of school children chose none, while the majority (43.9%) chose the 
smallest size presented. These findings are supported by evidence from practice; one study involving 
observed administration by nurses reported that 84% of children aged 4 to 6 years were able to 
swallow size #3 capsules intact (Mekmullica and Pancharoen, 2003). Similarly, Patchell et al. found 
that over 87% of children aged 3 to 17 years could swallow size #2 capsules, while Green et al. found 340 
that 73% of children could swallow hydroxyurea capsules, including over half by the age of 10 years 
(Patchell et al., 2002, Green et al., 2013).  
 
Using a similar approach with physical models, Batchelor et al. reported that over 97% of children 6 
to 7 years old and 85% of children aged 8 to 10 years old found 10mm caplet shaped tablets 345 
acceptable (Batchelor et al., 2013). Differences in the shape of tablet models (caplet versus round) 
may contribute to these differences in findings. In the present study, 46.4% of school children and 
34.1% of adolescents preferred round shaped tablets, versus 17.6% and 29.4% for oval or oblong 
shapes (the remaining participants showed no preference). Conversely, nearly half of all adults 
preferred oval or oblong shaped tablets.  350 
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A previous draft version of the EMA guideline proposed that tablets up to 10mm in diameter (medium 
tablets) would be deemed appropriate for school aged children and tablets up to 15mm in diameter 
(large tablets) for adolescents; however, this guidance was later removed for lacking a strong 
evidence base (Ranmal and Tuleu, 2013, EMA, 2011). This study suggests that 10mm diameter 355 
tablets would be unacceptable for around 40% of a general sample of children aged 6 to 11 years, 
while 13mm tablets would be unacceptable for nearly half of all adolescents. Research analysing 
reports of swallowing difficulties among adults suggest that this can arise when tablets are greater 
than approximately 8mm in diameter (Schiele et al., 2013, FDA, 2013). A review of all agreed PIPs 
by the end of 2011 found that tablets larger than 5mm had been approved for children aged 2 to 5 360 
years and tablets larger than 10mm for children aged 6 to 11 years; studies assessing the effect of 
modifications were not included in the list of binding terms, and details of the therapeutic indications 
for these products were not included in the review (van Riet-Nales et al., 2014b). However, as 
highlighted from this study, the therapeutic condition and availability of existing medicinal products 
should be considered alongside age. A recent US survey highlighted the vast differences in tablet and 365 
capsule sizes for the most commonly used paediatric medicines of the same dose, frequently between 
1 and 10mm in length, but in some cases even greater than this (Jacobsen et al., 2016). Due 
consideration of dosage form size is equally important for generics and off-patent medicines for use in 
paediatric patients, which may fall outside of the current regulatory remit. 
 370 
3.4. Practices 
In addition to attitudes and preferences, little is reported on the pragmatic approaches adopted by 
children and their caregivers to aid the administration of formulations that are not optimally designed 
for use in this population. Modifications include physical alterations to dosage forms, such as 
crushing or splitting tablets, opening capsules or mixing medicines with food or drink. This can be 375 
with the aim to improve acceptability, to facilitate administration, provide an appropriate dose, or a 
combination thereof. The nature, motives and consequences of these practices remains an under 
researched area; however, they have been widely reported amongst healthcare professionals 
(Skwierczynski and Conroy, 2008, Akram and Mullen, 2012, Richey et al., 2013) and as “coping 
17 
 
strategies” among children and their caregivers (Hansen et al., 2008, Adams et al., 2013, Bryson, 380 
2014).  
 
Overall, modifications were reported by 19.1% of school children and 17.1% of adolescents who had 
taken tablets or capsules in the two weeks preceding questionnaire completion. The most common 
modifications included crushing or splitting tablets and/or mixing medicines into food or drink. One 385 
limitation of the CALF study is that the purpose of modifications was not captured, for example, 
whether for provision of the appropriate dose, to aid administration, or both. Fewer than 10% of 
school children and adolescents taking tablets and capsules during the two weeks reported missing a 
dose due to swallowing difficulties. Among school children reporting modifications or non-
adherence, 75% were female, and one-third had a CHC. In adolescents, 60% were female and nearly 390 
half had a CHC. These rates highlight the need to further research the potential aforementioned 
gender effect. Evidence providing a scientific basis for such dosage form modifications is frequently 
lacking, though concerns about safety and efficacy are not unfounded. Potential and proven risks 
include calculation and practical errors (Wong et al., 2009), inaccuracy of dosing (Quinzler et al., 
2006, van Riet-Nales et al., 2014a) and harm to the individual who alters the medicine (Akram and 395 
Mullen, 2012). Altered bioavailability and palatability issues can also be of significant consequence 
(Best et al., 2011, Ferrarini et al., 2013).  
 
It is important for healthcare professionals to view children as autonomous social actors and provide 
relevant information directly to them as patients and consumers. In support of this, healthcare 400 
professionals were reported as the preferred source of information about medicines, with 80.4% of 
young people reporting that they would ask a doctor nurse or pharmacist if they had any questions or 
needed information. Just over half (56.3%) would ask family or friends, while 47.4% would look on 
the Internet. However, only 38.5% of respondents said they would read the patient information leaflet 
(PIL) and 13.6% would consult other written information about the medicine. This further emphasises 405 
the need for all elements of medicinal products to be adapted in consideration of the needs of children.  
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3.5. Child-centred research: from subjects to participants to contributors 
Despite the proposed paradigm shift towards child-centred research, there is much less empirical and 
methodological knowledge to guide this with younger populations compared to adults. Regulators 410 
suggest that acceptability of medicinal products should be preferably assessed with children 
themselves (EMA, 2013, Kozarewicz, 2014). This is advocated given sensory and perceptual 
differences across ages, and increasing evidence highlighting that attitudes and experiences are most 
accurately and reliably obtained from children themselves. However, it is imperative that the 
instruments developed are thoroughly tested and piloted in the intended population. As highlighted 415 
from this and other studies, children and young people’s active involvement and contribution early in 
development can facilitate the construction of age-appropriate instruments that are consistent with 
their competence, abilities and understanding (Stocks and Lum, 2016). 
 
3.6. Limitations 420 
While this study has addressed an important knowledge gap in the field, certain limitations are 
acknowledged. Given the paucity of evidence available, gaining insights into dosage form 
acceptability warranted exploratory, qualitative methods; however, for the same reason, collecting 
data from large representative samples was also needed, to help address the limit in information that 
currently hinders early paediatric formulation development. Nevertheless, further qualitative 425 
approaches are encouraged. Additionally, it is important to highlight the demographic of present 
study, which included a large proportion of respondents of Caucasian ethnicity and with a medium to 
high socioeconomic status. This may need to be considered in relation to the generalisability of 
findings, particularly in comparison to global and cross-cultural research. 
 430 
Importantly, this study has explored attitudes and perceived acceptability of dosage forms, which 
inherently may not capture actual habits in acute or chronic settings. The initial design involved 
comparing choices of tablet and capsule sizes with participants’ administration practices with current 
prescribed medicines, including collecting data around the specific dosage form attributes of these. 
Unfortunately, this was difficult to complete in practice within hospital settings and therefore 435 
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responses were based on perceptions rather than actual swallowability data. A follow-up study to 
assess the swallowability of capsules in school children was also difficult to set-up, and capturing 
such data on end-user acceptability may be difficult outside of clinical trials. The CALF study had 
some potential advantages, in that respondents could openly disclose their opinions and views 
(including barriers to acceptability) without any potential social desirability bias associated with 440 
reporting their own behaviours or practices with actual medicinal products. Nevertheless, there is 
further need for observed, tangible evidence to demonstrate acceptability, particularly in relation to 
swallowability of conventional tablet and capsule sizes. Access to wider evidence of swallowability in 
different age groups would help accelerate the development of medicines and avoid additional 
acceptability studies in children. 445 
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5. Conclusions 
Children have the right to access medicines that are appropriate to their unique needs and have 
adequate assurance of their quality, safety and efficacy. Likewise, they should also be entitled and 450 
encouraged to express their beliefs and opinions on matters that are pertinent to them, and this study 
reinforces the need for evidence-based research with children themselves, rather than solely relying 
on adult proxy reports.  Children as young as 6 years old provided invaluable feedback which 
benefited the design and development of the study as well as informing the research outcomes. Thus, 
it is feasible to undertake such research provided methodological approaches are adapted and 455 
structured, and due consideration is paid to children’s skills and abilities rather than perceived 
limitations. Moreover, data collection instruments should be comprehensively evaluated to provide 
assurance of the integrity of research findings. 
 
Age-appropriateness and acceptability are influenced by the characteristics of the target patient 460 
population and pharmaceutical properties of the medicinal product. As this facet of formulation 
development is in its infancy, there is little evidence to guide the specific aspects of assessment, 
appropriateness of methodologies, and expectations of satisfactory outcomes. The EMA guideline 
currently states that initial development should ”focus on a minimum number of acceptable dosage 
forms which are capable of meeting the needs of the majority of the children in the target age 465 
group(s)” (EMA, 2013). Given the extensive physiological and developmental differences across the 
population, it is unlikely that one single formulation could fulfil the needs and be deemed appropriate 
for all intended ages. Rather than a “one size fits all” approach, investigators should aim to tailor each 
formulation to cover the widest age range, ensuring pharmaceutical development strategies are 
effective and economical whilst providing authorised products for all target subsets.  470 
 
The need for systematic and transparent regulatory evaluation is well established, and understandably, 
developers seek to follow duly endorsed scientific advice. However, the impetus of this study was not 
to outline prescriptive criteria or recommendations in relation to specific patient parameters, and it 
does not eliminate the need for age-appropriateness and acceptability to be evaluated during 475 
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pharmaceutical development. The study findings aim to provide some guidance and rationale towards 
a formulation strategy for PIPs and PSPs that are submitted early in the drug development process. 
Provision of a suitable dosage form is fundamental in ensuring safe and effective pharmacotherapy, 
and this evidence can help inform industrial dosage form design and clinical choice. 
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Table 1 Overview of mixed-method studies and pre-testing techniques used to develop and evaluate 
the research material. 
Development Stage Setting 
Number of 
contributors/ 
participants  
Age  (years) 
Multi-disciplinary expert 
focus group 
University 8 [Adults] 
Focus groups with children 
and young people 
MCRN 
YPAG  
7  13 - 18  
MCRN 
YPAG  
10 8 – 17  
School 5 6 – 10  
School 6 12  -15 
Pre-testing:  cognitive and 
observational interviews 
 
MCRN 
YPAG 
4 8 - 11 
School 7 6 - 11 
School 7 12 - 14 
Assessment of test-retest 
reliability  
MCRN 
YPAG  
10  8 - 17 
School 5  6 - 11 
School 27 16-17 
Triangulation (convergent 
validity) using participants’ 
current medication practices 
 
Hospital 
 
44 7-17 
Hospital 
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Table 2 Demographics and health backgrounds of school children and adolescent participants 
 Overall 
[N=590] (%) 
School children 
aged 6-11 years 
[n=267] (%) 
Adolescents 
aged 12-17 years 
[n=323] (%) 
Age subgroup (years) 
6-7 16.1 35.5  
8-9 15.6 34.5  
10-11 13.6 30.0   
12-13 14.4  26.3 
14-15 14.4  26.3 
16-17 25.9  47.4 
Gender 
Male 47.1 51.3 43.7 
Female 52.9 48.7 56.3 
Ethnicity* 
White/Caucasian  48.7 55.1 43.3 
Asian   19.7 12.0 26.0 
Black 18.1 16.5 19.5 
Mixed/Multiple 9.8 11.2 8.7 
Other 3.7 5.2 2.5 
Socioeconomic status (SES) 
FASII  Low 17.1 21.0 13.9 
 Medium 39.2 38.2 39.9 
 High 28.1 20.2 34.7 
 Not reported†  15.6 20.6 11.5 
Chronic health condition  
Reported 37.3 36.7 37.8 
Not reported 62.7 63.3 62.2 
FASII: Family affluence scale 
* For brevity Canadian ethnicities have been combined with the broader UK groups: n=9 
‘East or Southeast Asian’, n=7 ‘West Asian/Arab’ and n=1 ‘South Asian’ have been 
classified as ‘Asian’ and n=1 ‘Latin, Central or South American’ has been classified as 
‘Other’.  
† This data was not collected from Canadian respondents in keeping with the requirements 
for ethical approval. 
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Table 3 Mean summated attitudinal scores for each dosage forms among school children (SC) and adolescents (A). Attitudes were measured using 3-item 5-
point scale measuring affective, behavioural and cognitive components.  
 Tablets Mini-tablets Capsules Chewables Orodispersibles Multiparticulates 
 SC A SC A SC A SC A SC A SC A 
Age subgroup (years) 
6-7 9.9  10.8  8.3  12.2  11.7  11.0  
8-9 10.0  11.0  9.0  12.0  11.8  11.5  
10-11 10.3  10.7  8.8  12.4  11.4  9.9  
12-13  11.0  10.8  9.5  11.4  11.2  9.3 
14-15  11.8  10.5  10.2  11.1  11.0  8.8 
16-17  11.7  11.1  10.3  11.1  10.9  9.6 
 p<0.001 ns p<0.001 p=0.002 ns p<0.001 
Gender 
Male 10.1 12.1 10.8 11.2 8.8 10.8 12.4 11.4 11.9 11.1 10.8 9.5 
Female 9.9 11.1 10.9 10.6 8.6 9.5 12.0 11.0 11.4 10.9 10.9 9.2 
 ns p=0.001 ns ns† ns p<0.001 ns ns ns ns ns ns 
Prior use 
Never 9.3 7.7 - - 8.2 8.3 11.3 10.2 11.3 10.4 10.8 9.3 
Rarely 9.3 10.4 - - 9.1 9.3 11.9 11.4 12.1 11.3 11.0 9.3 
Several times 10.8 11.9 - - 10.0 11.4 13.0 12.0 12.2 12.3 12.1 11.4 
Almost daily 11.5 12.5 - - 9.8 10.0 14.0 13.7 12.3 14.5  3.0 
 p<0.001 p<0.001 - - p=0.012 p<0.001 p<0.001 p<0.001 p<0.001 p=0.003 ns p<0.001 
Chronic health condition  
Reported 10.9 12.0 11.4 11.0 8.6 10.5 12.2 11.1 11.9 10.9 10.9 9.5 
Not reported 9.5 11.3 10.5 10.7 8.9 9.8 12.1 11.2 11.2 11.1 10.7 9.0 
 p<0.001 p=0.015 p<0.001 ns ns p=0.040 ns ns ns ns ns ns 
 
ns: not significant  
-: prior use of mini-tablets was not captured given the paucity of commercially available products  
† parametric test reached statistical significance but not corroborated by equivalent non-parametric test. 
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Figure 1 (a) Descriptors of the six solid oral dosage forms (SODFs) evaluated in the study; (b) the 3-
item, 5-point tripartite scale used to assess attitudes to dosage forms, including an affective 
component (like or dislike), cognitive component (easy or difficult to take), and behavioural 
component (willingness to take for children and young people, and willingness to purchase as an over 
the counter medicines for caregivers). Illustrated scale is from the young people questionnaire (YPQ); 
wording was adapted for the children’s questionnaire (CQ) and adult questionnaire (AQ).  
 
Figure 2 Attitudes and behavioural intent towards dosage forms in (a) school children and their 
caregivers and (b) adolescents and their caregivers. The lines indicate mean summated attitudinal 
scores from the tripartite scale. Bar graphs indicate the percentage of respondents reporting 
willingness to take the dosage form for school children and adolescents, and willingness to purchase 
the dosage form as an over-the-counter paediatric medicine among caregivers.  
 
Figure 3 Comparative preferences for dosage forms amongst school children and adolescents (a) 
Tablets or capsules, to compare single-unit dosage forms to be swallowed intact; (b) tablets or mini-
tablets, to compare single-unit versus multi-unit dosage forms administered directly; (c) chewables, 
orodispersible or multiparticulates, to compare specific preferences for more novel dosage forms.  
 
Figure 4 Acceptable (a) tablet and (b) capsule sizes that school children and adolescents perceived to 
be able to swallow, and that caregivers perceived that their child could swallow. The single largest 
size was selected for each dosage form.  
 
 
 
